Last updated: September 24, 2026
Tedizolid phosphate has a narrow but durable commercial position in acute bacterial skin and skin-structure infections (ABSSSI). Its once-daily, six-day regimen and activity against methicillin-resistant Staphylococcus aureus (MRSA) differentiate it from generic linezolid, but high acquisition cost, hospital formulary controls, and limited indication breadth constrain demand. The U.S. new chemical entity exclusivity period expired in 2019. The principal remaining U.S. patent risk is expected to center on composition, crystalline-form, prodrug, and method-of-use patents extending into the late 2020s.
Tedizolid Phosphate Market Dynamics, Patent Landscape, and Financial Trajectory
What is the FDA status of tedizolid phosphate?
Tedizolid phosphate is the active ingredient in Sivextro, marketed in the United States by Merck and commercially licensed to Melinta Therapeutics for U.S. promotion. The FDA approved Sivextro in June 2014 under NDA 205435 for treatment of ABSSSI caused by susceptible Gram-positive bacteria, including MRSA.[1]
The product is available in two dosage forms:
| Product |
Strength |
Administration |
Standard duration |
| Sivextro tablets |
200 mg |
Oral, once daily |
Six days |
| Sivextro injection |
200 mg |
Intravenous, once daily |
Six days |
Tedizolid is an oxazolidinone antibacterial. Its principal clinical competitor is linezolid, which is available as a low-cost generic and is generally administered twice daily for 10 to 14 days. Tedizolid’s commercial proposition is a shorter treatment course, once-daily dosing, and a lower apparent risk of myelosuppression in short-course use.[1]
The approved indication is narrower than the broad hospital use of many competing antibiotics. Sivextro is not approved for pneumonia, bloodstream infection, urinary tract infection, or osteomyelitis. That limits its role in hospitals where empiric therapy must cover a wider range of pathogens.
When does tedizolid phosphate lose exclusivity?
The key U.S. exclusivity dates are:
| Exclusivity or patent event |
Date or period |
Commercial impact |
| FDA approval |
June 20, 2014 |
U.S. launch of Sivextro |
| New chemical entity exclusivity |
Expired June 20, 2019 |
ANDA pathway became available |
| Pediatric exclusivity |
No major commercial extension publicly associated with the core product |
Did not materially reset the patent estate |
| Principal product patent family |
Late 2020s, depending on patent and jurisdiction |
Potential barrier to immediate generic launch |
| Generic entry window |
Potentially after final enforceable patent expiry or earlier through settlement |
Depends on Paragraph IV filings and litigation outcomes |
The five-year NCE exclusivity period ended in 2019. That date removed the principal FDA exclusivity barrier, but it did not necessarily permit immediate generic entry because listed patents may block approval or launch.
The commercial patent cliff is therefore later than the regulatory exclusivity cliff. For business planning, tedizolid should be analyzed as a product with expired NCE exclusivity but continuing patent protection.
What patents protect Sivextro and tedizolid phosphate?
The tedizolid estate includes patents directed to the oxazolidinone chemical series, phosphate prodrug technology, pharmaceutical compositions, solid forms, and treatment methods. Public patent records associate major U.S. rights with Trius Therapeutics and later with Cubist Pharmaceuticals and Merck affiliates.
Representative patent families include:
| Patent subject |
Representative U.S. patent |
Principal protection |
| Tedizolid and related oxazolidinones |
U.S. patent family originating with Trius Therapeutics |
Active-agent and chemical structure claims |
| Phosphate prodrug technology |
U.S. Patent No. 8,822,438 |
Tedizolid phosphate and related prodrug claims |
| Solid-state and formulation technology |
Related continuation and formulation families |
Crystalline form, stability, and dosage-form protection |
| Treatment methods |
Later method-of-use families |
Use of tedizolid in defined bacterial infections or treatment regimens |
The commercially important issue is claim overlap. An ANDA applicant could challenge the active-ingredient patent, the phosphate prodrug patent, formulation patents, or method-of-use patents separately. A challenge to one patent does not automatically eliminate all patent risk.
Patent-term calculations can also differ by patent because of priority claims, patent-term adjustment, terminal disclaimers, and any patent-term extension. A definitive launch date requires review of the current FDA Orange Book, patent certificates, and the relevant U.S. Patent and Trademark Office records.
What formulations are protected by tedizolid patents?
The main product-specific formulation exposures are:
- 200 mg immediate-release oral tablets.
- 200 mg intravenous infusion.
- Tedizolid phosphate as a water-soluble prodrug.
- Solid-state and crystalline forms.
- Formulation stability and manufacturing processes.
The prodrug is commercially important because tedizolid itself has limited aqueous solubility. The phosphate moiety supports intravenous formulation and oral dosage-form development. A generic applicant may be able to copy the approved dosage strength while designing around particular crystalline-form or manufacturing claims, but the practical risk depends on the scope and enforceability of each issued claim.
What is the Orange Book status of Sivextro?
Sivextro is listed in the FDA Orange Book under NDA 205435. Orange Book listings are central to generic timing because they identify patents submitted by the NDA holder and trigger the statutory Paragraph IV framework when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or not infringed.[2]
The product’s regulatory profile creates three separate entry questions:
- Whether an ANDA applicant has filed a Paragraph IV certification.
- Whether Merck or the relevant patent owner files infringement litigation within the statutory period.
- Whether the challenged patents remain enforceable when the ANDA is otherwise approvable.
A method-of-use patent can create a narrower risk than a composition patent. Under a section viii statement, an ANDA applicant may attempt to omit a patented indication from its labeling. That strategy is more practical when the patent covers a discrete indication rather than the drug, salt, or dosage form itself.
Which companies are challenging tedizolid phosphate patents?
No major publicly reported U.S. Paragraph IV litigation against Sivextro had materially changed the product’s commercial position through the public record available through mid-2024. Public generic availability also remained limited relative to linezolid and other oxazolidinones.
Potential challengers are most likely to include:
- Large generic companies with hospital anti-infective portfolios.
- Indian and European manufacturers seeking U.S. ANDA approval.
- Contract development and manufacturing organizations partnering with generic applicants.
- Specialty generic companies targeting injectable anti-infective products.
The absence of a visible launch does not establish that no ANDA has been filed. FDA does not routinely disclose the identity of all ANDA applicants before approval or litigation becomes public.
How strong is the tedizolid phosphate patent estate?
The estate is moderately strong commercially but weaker than a fully protected, still-exclusive branded product.
Factors supporting patent strength
- Tedizolid phosphate is a defined prodrug rather than a simple repackaging of linezolid.
- The product has multiple potential patent layers, including chemical, prodrug, solid-form, and method claims.
- A generic applicant may need to address both oral and injectable product issues.
- Manufacturing and solid-state claims can increase development and litigation costs.
Factors limiting patent strength
- NCE exclusivity expired in 2019.
- The product is a small molecule, so it has no biologic interchangeability barrier.
- Linezolid provides a well-established low-cost clinical substitute.
- A generic applicant can pursue patent-by-patent invalidity and non-infringement theories.
- The approved indication is narrow, reducing the commercial value of prolonged litigation.
The estate is therefore more likely to delay generic entry than to prevent it permanently. Patent duration into the late 2020s can still support meaningful value because hospital anti-infective products often retain branded pricing until an approved generic establishes formulary access.
How has tedizolid phosphate performed financially?
Merck has not historically reported Sivextro as a standalone material revenue line in its public financial statements. Sales are generally embedded within broader product categories or are not separately disclosed. Melinta is privately held, and its public financial reporting does not provide a reliable, continuous Sivextro revenue series.
The financial trajectory is best described through commercial milestones rather than reported annual revenue:
| Period |
Commercial development |
Financial implication |
| 2014-2015 |
FDA approval and launch under Cubist/Merck ownership |
Initial branded pricing and hospital uptake |
| 2016-2018 |
Expansion of clinical adoption in ABSSSI |
Growth constrained by generic linezolid and stewardship controls |
| 2019 |
Expiration of five-year NCE exclusivity; U.S. commercialization rights licensed to Melinta |
Merck reduced direct commercial exposure; generic risk increased |
| 2020-2022 |
Specialty anti-infective commercialization through Melinta |
Sales dependent on hospital contracting and formulary positioning |
| 2023-mid-2024 |
Continued branded positioning without a visible broad generic launch |
Ongoing late-life revenue, but limited growth potential |
Sivextro’s revenue profile is likely characterized by high gross-to-net pressure and concentrated institutional demand. Hospital systems negotiate antibiotic pricing through group purchasing organizations, formularies, and antimicrobial stewardship programs. This limits the ability to sustain a large premium over generic linezolid.
No credible public data supports a standalone valuation based on Sivextro revenue alone. A financial model should treat the product as a mature specialty anti-infective with declining long-term volume and residual value from patent-protected pricing.
How does tedizolid compare with linezolid and other MRSA drugs?
| Drug |
Ownership status |
Typical role |
Commercial advantage |
Principal weakness |
| Tedizolid |
Branded Sivextro; U.S. rights commercialized by Melinta |
ABSSSI |
Once daily for six days; oral and IV options |
High price; narrow label |
| Linezolid |
Generic |
MRSA and other Gram-positive infections |
Low cost; broad clinical familiarity; oral bioavailability |
Twice-daily dosing; hematologic and interaction concerns |
| Vancomycin |
Generic |
Serious MRSA infections |
Extensive hospital experience |
IV administration; monitoring and nephrotoxicity |
| Daptomycin |
Branded and generic |
Complicated Gram-positive infections |
Strong hospital positioning |
IV only; myopathy monitoring |
| Ceftaroline |
Branded and generic |
MRSA and selected bacterial infections |
Beta-lactam profile with MRSA activity |
IV only; higher treatment burden |
| Dalbavancin |
Branded |
Long-acting ABSSSI treatment |
One- or two-dose administration |
High acquisition cost |
| Oritavancin |
Branded |
Single-dose ABSSSI treatment |
One-time IV dosing |
Limited utilization and high cost |
Tedizolid competes most directly with linezolid, not with long-acting lipoglycopeptides. Linezolid sets the price ceiling for oral oxazolidinone therapy. Dalbavancin and oritavancin compete for outpatient and discharge-management cases where avoiding daily IV treatment has greater value.
What generic entry risks exist for tedizolid?
The principal generic scenarios are:
Scenario 1: Delayed entry until late-decade patent expiry
This is the base commercial scenario if no successful Paragraph IV challenge emerges. Sivextro retains branded pricing but experiences declining demand as clinicians favor lower-cost alternatives.
Scenario 2: First-filer launch after patent settlement
A settlement could grant a generic applicant an agreed launch date before the latest listed patent expires. Such an outcome would create a rapid revenue decline for the branded product and could give the first filer temporary generic exclusivity.
Scenario 3: At-risk launch after patent invalidation or non-infringement
An ANDA applicant could launch before the nominal patent expiry if litigation produces a favorable judgment or if the patent owner does not obtain an injunction. This would create the sharpest price erosion.
Scenario 4: Limited-label generic entry
A generic applicant could remove a patented indication through a section viii carve-out. This might permit entry while preserving some branded use, but the commercial effect would depend on whether hospitals treat the generic as substitutable across the same clinical setting.
The most important commercial variable is not the number of patents alone. It is whether the remaining enforceable claims cover the active moiety, the phosphate salt, or only narrower formulations and methods.
What manufacturing and geographic barriers affect tedizolid?
Tedizolid phosphate has fewer manufacturing barriers than biologic drugs, but it is not a simple commodity antibiotic. Potential barriers include:
- Control of solid form and polymorphism.
- Reproducible synthesis of the phosphate prodrug.
- Impurity control and stability.
- Injectable formulation and sterile manufacturing.
- Bioequivalence for the oral product.
- Establishment of reliable hospital supply.
Outside the United States, patent duration and regulatory exclusivity vary by jurisdiction. European, Japanese, Canadian, and emerging-market launch dates may diverge because national patent grants, supplementary protection certificates, data exclusivity, and local litigation outcomes differ.
The product has no biosimilar risk. Tedizolid is a chemically defined small molecule and would enter through generic-drug pathways, not the biosimilar pathway under the Public Health Service Act.
What licensing deals affect tedizolid phosphate?
Merck licensed U.S. commercialization of Sivextro to Melinta in 2019 while retaining broader ownership of the product rights. The arrangement shifted sales execution to a specialty anti-infective company with an established hospital portfolio.[3]
The license matters commercially because:
- Merck no longer carried the same direct promotional burden in the United States.
- Melinta could combine Sivextro with other hospital anti-infective products.
- Revenue visibility became lower because Melinta is privately held.
- Contract terms, royalty rates, minimum commitments, and net sales were not publicly disclosed in a detailed product-level format.
No material licensing transaction has publicly transformed the global tedizolid market in the same way as the U.S. commercialization agreement.
What patent litigation affects Sivextro?
The public record through mid-2024 did not show a major, market-disrupting U.S. patent judgment involving Sivextro. The absence of headline litigation leaves the key risk concentrated in future ANDA filings and patent-term analysis.
A meaningful litigation event would likely involve:
- A Paragraph IV notice letter.
- A 30-month stay triggered by timely infringement litigation.
- Challenge to the phosphate prodrug or active-ingredient claims.
- Dispute over solid-form or formulation claims.
- Settlement with a defined generic launch date.
Key Takeaways
- Tedizolid phosphate is a branded oxazolidinone for six-day treatment of ABSSSI.
- Sivextro’s FDA approval date was June 20, 2014.
- Five-year NCE exclusivity expired June 20, 2019.
- Merck licensed U.S. commercialization to Melinta, reducing public visibility into product-level revenue.
- The main competitive threat is generic linezolid, which is cheaper and clinically familiar.
- The remaining patent estate is more likely to delay generic entry than permanently prevent it.
- Product-level revenue is not separately disclosed in a dependable public series.
- The drug has no biosimilar risk because it is a small molecule.
- Future value depends on patent durability, hospital formulary retention, and the timing of the first approved generic.
- The principal commercial risk is a late-decade generic launch followed by rapid price erosion.
FAQs About Tedizolid Phosphate Market and Patent Risk
Is tedizolid phosphate still under FDA exclusivity?
No. The five-year NCE exclusivity period expired in June 2019. Patent protection may continue after regulatory exclusivity ends.
Is Sivextro the same drug as tedizolid?
Sivextro contains tedizolid phosphate. Tedizolid is the active antibacterial moiety generated from the phosphate prodrug.
Can generic manufacturers copy both the tablet and injection?
They can pursue ANDA approval for either dosage form, but each product must satisfy FDA bioequivalence, quality, manufacturing, and patent-certification requirements.
Does tedizolid face biosimilar competition?
No. Tedizolid is a small-molecule antibiotic and faces conventional generic competition rather than biosimilar competition.
What would cause the largest decline in Sivextro revenue?
An approved generic with broad substitutability for the 200 mg oral tablet would likely cause the largest revenue decline because oral linezolid already establishes a low-cost alternative and hospitals can rapidly revise formularies.
References
- U.S. Food and Drug Administration. (2014). Sivextro (tedizolid phosphate) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Merck & Co., Inc. (2020). Annual report 2019.
- U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,822,438: Phosphate prodrugs of oxazolidinone antibiotics.
- Merck & Co., Inc. (2015). Annual report 2014.
